Effectiveness of the Personalized Responses & Integrated Systems for Metabolism (PRISM) on Improving Insulin Resistance Among Adults With Metabolic Syndrome: A Pilot Study (PRISM-I) (PRISM-I)
2026년 7월 15일 업데이트: Jocelyn Chew, National University Health System, Singapore
The primary objective of the Personalized Responses & Integrated Systems for Metabolism (PRISM-I) pilot study is to assess the feasibility of conducting a definitive randomized controlled trial evaluating precision lifestyle interventions for improving insulin resistance in adults with metabolic syndrome.
연구 개요
상태
아직 모집하지 않음
상세 설명
Specific objectives are to:
- Evaluate the feasibility and acceptability of the PRISM intervention and study procedures, including participant recruitment, retention, adherence, intervention delivery, and digital platform usability.
- Explore the preliminary effects of the four lifestyle interventions (time-restricted eating, increased physical activity, low-glycaemic load diet, and sleep hygiene) on insulin resistance, measured using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).
- Examine the preliminary effects of the interventions on biochemical, anthropometric, behavioural, cognitive, and psychological outcomes.
- Explore the potential behavioural and physiological pathways through which the lifestyle interventions may influence insulin resistance to inform the design of the definitive PRISM trial.
연구 유형
중재적
등록 (추정된)
200
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Jocelyn Chew
- 전화번호: +6565168687
- 이메일: dbi-lab@nus.edu.sg
연구 장소
-
-
-
Singapore, 싱가포르, 117597
- National University of Singapore
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
Participants will be included for if they are:
- (1) adults aged 21-70 years old;
- (2) willing and able to comply with using a CGM, smart ring, food logging app
- (3) able to provide written informed consent;
- (4) English-speaking and literate;
- (5) meet the inclusion criteria for metabolic syndrome and insulin resistance.
- The criteria for insulin resistance is HOMA-IR ≥ 2.5.
- The criteria for metabolic syndrome is to have high waist circumference (≥ 80cm for females and ≥ 90cm for males); and any two of the four below:
- (1) raised triglycerides: 1.7 mmol/L or on treatment;
- (2) reduced HDL cholesterol: < 1.0 mmol/L (40 mg/dL) in men, < 1.3 mmol/L (50 mg/dL) in women, or on treatment;
- (3) high blood pressure: 130/85 mmHg or on treatment; or
- (4) raised fasting glucose: 5.6 mmol/L (100 mg/dL) or previously diagnosed with T2DM
Exclusion Criteria:
Participants will be excluded from both phases if they are:
- (1) on insulin therapy;
- (2) are pregnant or lactating;
- (3) have a medical condition or are on a treatment that may interfere with study participation or metabolic assessments, as determined by the study investigators;
- (4) currently participating in other lifestyle modification programs.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Control
At baseline, participants will undergo blood collection, stool sample collection, questionnaires, and cognitive and physical assessments.
They will be provided with an Oura Ring and continuous glucose monitor (CGM) to monitor physiological and behavioral measures throughout the study.
Participants will use the eTRIP© app to log meals and the Oura app to record physical activity.
General healthy lifestyle information on diet, physical activity, and sleep will be provided at baseline.
Participants assigned to the control group will continue their usual lifestyle throughout the 10-week study and will not receive any targeted lifestyle intervention.
At Week 5, participants will attend a study visit for interim assessments and replacement of the CGM for the remainder of the study.
Baseline assessments will be repeated at Week 10.
|
|
|
실험적: PRISM
At baseline, participants will undergo blood collection, stool sample collection, questionnaires, and cognitive and physical assessments.
They will be provided with an Oura Ring and continuous glucose monitor (CGM) to monitor physiological and behavioural measures throughout the study.
Participants will use the eTRIP© app to log meals and the Oura app to record physical activity.
General healthy lifestyle advice on diet, physical activity, and sleep will be provided at baseline.
At the end of the 2-week baseline assessment, participants will be randomized to one of four lifestyle interventions: time-restricted eating, increased physical activity, a low-glycemic load diet, or sleep hygiene.
At Week 5, participants will attend a study visit and be randomized to receive an additional intervention from one of the remaining three lifestyle domains, beginning in Week 6. Baseline assessments will be repeated at Week 10.
|
Following a 2-week baseline assessment, participants will begin a time-restricted eating (TRE) intervention by consuming all meals within a self-selected 8-hour eating window and fasting for the remaining 16 hours each day.
They will measure blood ketone levels daily before breaking their fast using a glucometer.
At Week 6, participants will be randomly assigned an additional lifestyle intervention (physical activity, low glycemic load diet, or sleep hygiene).
Following a 2-week baseline assessment, participants will begin a physical activity intervention.
They will be instructed to complete home-based resistance training three times per week and aerobic interval training twice per week using a guided exercise programme.
Exercise sessions will be performed independently without direct supervision.
Participants will also be encouraged to aim for at least 8,000 steps daily, take a 15-minute walk after lunch and dinner where feasible, and break up prolonged sitting every 30-60 minutes with light movement or standing.
At Week 6, participants will be randomly assigned an additional lifestyle intervention (time-restricted eating, low-glycemic load diet, or sleep hygiene).
Following a 2-week baseline assessment, participants will begin a low-glycaemic load (GL) diet intervention.
They will be instructed to replace high-GL foods with lower-GL alternatives, reduce their intake of refined carbohydrates, sugary foods and beverages, and ultra-processed foods, and follow healthy meal composition and meal sequencing principles.
At Week 6, participants will be randomly assigned an additional lifestyle intervention (time-restricted eating, physical activity, or sleep hygiene).
Following a 2-week baseline assessment, participants will begin a sleep hygiene intervention.
They will be instructed to adopt healthy sleep habits, including maintaining a regular sleep schedule with adequate sleep duration, practicing good bedtime routines, and optimizing the sleep environment to improve sleep quality.
At Week 6, participants will be randomly assigned an additional lifestyle intervention (time-restricted eating, physical activity, or a low-glycemic load diet).
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
기간: At baseline, Week 10
|
Insulin resistance will be assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated as: HOMA-IR = (fasting plasma insulin × fasting plasma glucose) / 22.5 Higher HOMA-IR values indicate greater insulin resistance, whereas lower values indicate improved insulin sensitivity (reduced insulin resistance). |
At baseline, Week 10
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Glycated haemoglobin (HbA1c) (%)
기간: At baseline, Week 10
|
Glycated haemoglobin (HbA1c) reflects average blood glucose levels over the preceding two to three months and is measured using standard laboratory blood analysis.
Higher values indicate poorer long-term glycaemic control.
|
At baseline, Week 10
|
|
Fasting plasma glucose (mmol/L)
기간: At baseline, Week 10
|
Fasting blood glucose is a biochemical measure of blood glucose concentration after an overnight fast, measured using standard laboratory blood analysis.
Higher values indicate poorer glycaemic control.
|
At baseline, Week 10
|
|
Fasting Insulin (µIU/mL)
기간: At baseline, Week 10
|
Fasting plasma insulin is a biochemical marker measured using standard laboratory blood analysis following an overnight fast.
Higher values indicate greater insulin resistance and impaired glucose metabolism.
|
At baseline, Week 10
|
|
Total cholesterol (mmol/L)
기간: At baseline, Week 10
|
Total cholesterol is a lipid biomarker measured using standard laboratory blood analysis to assess overall blood cholesterol levels.
Higher values indicate poorer lipid profiles and increased cardiometabolic risk.
|
At baseline, Week 10
|
|
High-density lipoprotein cholesterol (HDL-C) (mmol/L)
기간: At baseline, Week 10
|
High-density lipoprotein cholesterol (HDL-C) is a lipid biomarker measured using standard laboratory blood analysis to assess protective cholesterol levels.
Lower values indicate poorer lipid profiles and increased cardiometabolic risk.
|
At baseline, Week 10
|
|
Low-density lipoprotein cholesterol (LDL-C) (mmol/L)
기간: At baseline, Week 10
|
Low-density lipoprotein cholesterol (LDL-C) is a lipid biomarker measured using standard laboratory blood analysis to assess atherogenic cholesterol levels.
Higher values indicate poorer lipid profiles and increased cardiovascular risk.
|
At baseline, Week 10
|
|
Cholesterol/HDL ratio
기간: At baseline, Week 10
|
The total cholesterol to HDL cholesterol ratio is calculated from standard laboratory blood analysis and is used to assess cardiovascular risk.
Higher values indicate a poorer lipid profile and increased cardiometabolic risk.
|
At baseline, Week 10
|
|
Triglycerides (mmol/L)
기간: At baseline, Week 10
|
Triglycerides are a lipid biomarker measured using standard laboratory blood analysis to assess circulating triglyceride levels.
Higher values indicate poorer lipid profiles and increased cardiometabolic risk.
|
At baseline, Week 10
|
|
Lipoprotein a (nmol/L)
기간: At baseline, Week 10
|
Lipoprotein(a) is an advanced lipid biomarker measured using standard laboratory blood analysis to assess inherited cardiovascular risk.
Higher values are associated with increased risk of atherosclerotic cardiovascular disease
|
At baseline, Week 10
|
|
Apolipoprotein A1 (g/L)
기간: At baseline, Week 10
|
Apolipoprotein A1 (ApoA1) is a lipid biomarker measured using standard laboratory blood analysis to assess the major protein component of HDL cholesterol.
Higher values generally indicate a more favourable lipid profile.
|
At baseline, Week 10
|
|
Apolipoprotein B (g/L)
기간: At baseline, Week 10
|
Apolipoprotein B (ApoB) is a lipid biomarker measured using standard laboratory blood analysis to assess the number of atherogenic lipoprotein particles.
Higher values indicate increased cardiovascular risk.
|
At baseline, Week 10
|
|
Apolipoprotein B/ A1 ratio
기간: At baseline, Week 10
|
The Apolipoprotein B/A1 ratio is calculated from standard laboratory blood analysis and reflects the balance between atherogenic and protective lipoproteins.
Higher values indicate increased cardiovascular risk
|
At baseline, Week 10
|
|
High-sensitivity C-reactive protein (hs-CRP) (mg/L)
기간: At baseline, Week 10
|
High-sensitivity C-reactive protein (hs-CRP) is an inflammatory biomarker measured using standard laboratory blood analysis to assess low-grade systemic inflammation.
Higher values indicate greater systemic inflammation and increased cardiometabolic risk.
|
At baseline, Week 10
|
|
Total protein (g/L)
기간: At baseline, Week 10
|
Total protein is measured using standard laboratory blood analysis to assess the combined concentration of albumin and globulins in blood.
|
At baseline, Week 10
|
|
Albumin (g/L)
기간: At baseline, Week 10
|
Albumin is a plasma protein measured using standard laboratory blood analysis to assess nutritional status and liver function.
Lower values may indicate impaired liver function, malnutrition, or inflammation.
|
At baseline, Week 10
|
|
Globulin (g/L)
기간: At baseline, Week 10
|
Globulin is measured using standard laboratory blood analysis to assess immune and inflammatory proteins in the blood.
|
At baseline, Week 10
|
|
A/G ratio
기간: At baseline, Week 10
|
The albumin-to-globulin (A/G) ratio is calculated from serum albumin and globulin concentrations and is used to assess liver function, nutritional status, and inflammatory conditions.
|
At baseline, Week 10
|
|
Bilirubin (µmol/L)
기간: At baseline, Week 10
|
Bilirubin is measured using standard laboratory blood analysis to assess liver function and bilirubin metabolism.
|
At baseline, Week 10
|
|
Alkaline phosphatase (ALP) (U/L)
기간: At baseline, Week 10
|
Alkaline phosphatase (ALP) is a liver enzyme measured using standard laboratory blood analysis to assess liver and biliary tract function.
|
At baseline, Week 10
|
|
Alanine aminotransferase (ALT/SGPT) (U/L)
기간: At baseline, Week 10
|
Alanine aminotransferase (ALT/SGPT) is a liver enzyme measured using standard laboratory blood analysis to assess liver cell injury.
|
At baseline, Week 10
|
|
Aspartate aminotransferase (AST/SGOT) (U/L)
기간: At baseline, Week 10
|
Aspartate aminotransferase (AST/SGOT) is a liver enzyme measured using standard laboratory blood analysis to assess liver and muscle cell injury.
Higher values may indicate liver damage or other tissue injury.
|
At baseline, Week 10
|
|
Blood pressure (mmHg)
기간: At baseline, Week 10
|
Both systolic and diastolic blood pressure will be assessed.
|
At baseline, Week 10
|
|
Montreal Cognitive Assessment (MoCA)
기간: At baseline, Week 10
|
The Montreal Cognitive Assessment is a validated screening instrument designed to detect mild cognitive impairment.
It assesses multiple cognitive domains, including attention and concentration, executive function, memory, language, visuospatial skills, abstraction, calculation, and orientation.
Total scores range from 0 to 30, with higher scores indicating better cognitive function.
|
At baseline, Week 10
|
|
Hand grip strength (kg)
기간: At baseline, Week 10
|
Hand grip strength will be measured using a Jamar dynamometer as an indicator of muscle strength.
Higher values indicate greater muscle strength.
|
At baseline, Week 10
|
|
Weight (kg)
기간: At baseline, Weeks 5,10
|
At baseline, Weeks 5,10
|
|
|
Waist circumference (cm)
기간: At baseline, Weeks 5,10
|
At baseline, Weeks 5,10
|
|
|
Body mass index (BMI) (kg/m²)
기간: At baseline, Weeks 5,10
|
Body mass index (BMI) will be calculated as weight (kg)/height² (m²).
Lower values indicate lower overall adiposity.
|
At baseline, Weeks 5,10
|
|
Percentage Body Fat (%)
기간: At baseline, Weeks 5,10
|
Percentage body fat will be estimated using bioelectrical impedance analysis (InBody 120).
Lower values indicate lower adiposity.
|
At baseline, Weeks 5,10
|
|
Body Fat Mass (kg)
기간: At baseline, Weeks 5,10
|
Measured using InBody 120.
|
At baseline, Weeks 5,10
|
|
Visceral Fat Level
기간: At baseline, Week 10
|
Visceral fat level will be estimated using bioelectrical impedance analysis (InBody 120).
Lower values indicate reduced visceral adiposity.
|
At baseline, Week 10
|
|
ABSI (body shape index)
기간: At baseline, Weeks 5,10
|
A Body Shape Index (ABSI) is calculated from waist circumference, height, and body weight to assess central adiposity independently of BMI.
Higher values indicate greater abdominal obesity and cardiometabolic risk.
|
At baseline, Weeks 5,10
|
|
BRI (body roundness index)
기간: At baseline, Weeks 5,10
|
Body Roundness Index (BRI) is calculated from height and waist circumference to estimate body fat distribution and central adiposity.
Higher values indicate greater abdominal adiposity and cardiometabolic risk.
|
At baseline, Weeks 5,10
|
|
Three Factor Eating Questionnaire (TFEQ)
기간: At baseline, Week 10
|
The Three-Factor Eating Questionnaire-Revised 18 is a validated self-administered instrument used to assess eating-related behaviours.
It measures three domains: cognitive restraint, uncontrolled eating, and emotional eating.
Scores are calculated separately for each domain and transformed to a 0-100 scale, with higher scores indicating greater levels of the respective eating behaviour.
|
At baseline, Week 10
|
|
International Physical Activity Questionnaire Short-Form (IPAQ-SF)
기간: At baseline, Week 10
|
The International Physical Activity Questionnaire - Short Form is a validated self-administered questionnaire used to assess self-reported physical activity levels over the previous 7 days.
It captures the frequency and duration of walking, moderate-intensity activity, vigorous-intensity activity, and time spent sitting.
Responses are used to calculate total physical activity expressed as MET-minutes/week.
There is no fixed minimum or maximum score; higher MET-minutes/week indicate higher levels of physical activity.
|
At baseline, Week 10
|
|
Generalized Anxiety Disorder 7-item (GAD-7)
기간: At baseline, Week 10
|
The Generalized Anxiety Disorder 7-item questionnaire is a validated self-administered screening instrument used to assess the frequency of anxiety symptoms over the previous 2 weeks.
Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.
|
At baseline, Week 10
|
|
Patient Health Questionnaire-9 (PHQ-9)
기간: At baseline, Week 10
|
The Patient Health Questionnaire-9 is a validated self-administered screening instrument used to assess the frequency of depressive symptoms over the previous 2 weeks.
Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.
|
At baseline, Week 10
|
|
Perceived Stress Scale (PSS-10)
기간: At baseline, Week 10
|
The Perceived Stress Scale-10 is a validated self-administered questionnaire used to assess the degree to which individuals perceive situations in their lives as stressful over the previous month.
Total scores range from 0 to 40, with higher scores indicating greater perceived stress.
|
At baseline, Week 10
|
|
Big Five Inventory - 44 item (BFI-44)
기간: At baseline, Week 10
|
The Big Five Inventory-44 is a validated self-administered questionnaire used to assess personality across five domains: openness, conscientiousness, extraversion, agreeableness, and neuroticism.
Scores are calculated separately for each domain; there is no overall total score.
Domain scores are typically calculated as the mean of the items within each domain and range from 1 to 5, with higher scores indicating greater expression of the respective personality trait.
As this is a descriptive measure of personality, higher scores do not represent universally better or worse outcomes.
|
At baseline, Week 10
|
|
Sleep Hygiene Index (SHI)
기간: At baseline, Week 10
|
The Sleep Hygiene Index is a validated 13-item self-administered questionnaire that assesses behaviours associated with sleep hygiene.
Total scores range from 13 to 65, with higher scores indicating poorer sleep hygiene practices.
|
At baseline, Week 10
|
|
Gut microbiome
기간: At baseline, Week 10
|
At baseline, Week 10
|
|
|
Resting heart rate (beats/min)
기간: Baseline through Week 10
|
Resting heart rate measured using the Oura Ring.
Resting heart rate represents the average heart rate during periods of rest.
Lower values generally indicate better cardiovascular fitness.
|
Baseline through Week 10
|
|
Heart rate variability (ms)
기간: Baseline through Week 10
|
Heart rate variability measured using the Oura Ring.
HRV reflects variation in the time interval between successive heartbeats and is an indicator of autonomic nervous system function.
Higher values generally indicate better autonomic regulation and recovery.
|
Baseline through Week 10
|
|
Heart rate recovery (beats/min)
기간: Baseline through Week 10
|
Heart rate recovery measured using the Oura Ring.
Heart rate recovery represents the reduction in heart rate following physical activity and reflects cardiovascular recovery capacity.
Higher values indicate faster recovery and better cardiovascular fitness.
|
Baseline through Week 10
|
|
Sleep duration (hours)
기간: Baseline through Week 10
|
Sleep duration measured using the Oura Ring.
Sleep duration represents the total amount of sleep obtained per night.
Higher values generally indicate longer sleep duration.
|
Baseline through Week 10
|
|
Sleep quality score (0-100)
기간: Baseline through Week 10
|
Sleep quality score measured using the Oura Ring.
Scores range from 0 to 100, with higher scores indicating better sleep quality.
|
Baseline through Week 10
|
|
Daily step count (steps/day)
기간: Baseline through Week 10
|
Daily step count measured using the Oura Ring.
Step count represents the total number of steps accumulated per day.
Higher values indicate greater daily physical activity.
|
Baseline through Week 10
|
|
Activity intensity minutes (minutes/day)
기간: Baseline through Week 10
|
Activity intensity minutes measured using the Oura Ring.
This metric represents the daily duration of moderate-to-vigorous physical activity.
Higher values indicate greater participation in physical activity.
|
Baseline through Week 10
|
|
Energy expenditure (kcal/day)
기간: Baseline through Week 10
|
Energy expenditure measured using the Oura Ring.
This metric represents the estimated daily energy expenditure from physical activity.
Higher values indicate greater energy expenditure.
|
Baseline through Week 10
|
|
Mean glucose (mmol/L)
기간: Baseline through Week 10
|
Mean glucose concentration measured using continuous glucose monitoring.
Mean glucose represents the average glucose concentration over the monitoring period.
Lower values generally indicate better glycaemic control.
|
Baseline through Week 10
|
|
Coefficient of variation (%)
기간: Baseline through Week 10
|
Coefficient of variation of glucose measured using continuous glucose monitoring.
CV reflects glucose variability relative to mean glucose concentration.
Lower values indicate more stable glucose levels and better glycaemic control.
|
Baseline through Week 10
|
|
Time Below Range (TBR, %)
기간: Baseline through Week 10
|
Percentage of time spent below the target glucose range (<3.9 mmol/L), measured using continuous glucose monitoring.
Lower values indicate less time spent in hypoglycaemia and better glycaemic control.
|
Baseline through Week 10
|
|
Time In Range (TIR, %)
기간: Baseline through Week 10
|
Percentage of time spent within the target glucose range (3.9-10.0
mmol/L), measured using continuous glucose monitoring.
Higher values indicate better glycaemic control.
|
Baseline through Week 10
|
|
Time Above Range (TAR, %)
기간: Baseline through Week 10
|
Percentage of time spent above the target glucose range (>10.0 mmol/L), measured using continuous glucose monitoring.
Lower values indicate less hyperglycaemia and better glycaemic control.
|
Baseline through Week 10
|
|
Postprandial glucose excursion (PPGE) (mmol/L)
기간: Baseline through Week 10
|
Postprandial glucose excursion measured using continuous glucose monitoring.
PPGE is calculated as the difference between peak glucose concentration and pre-meal glucose concentration within 2 hours after the start of a meal.
Higher values indicate greater postprandial glucose excursions.
|
Baseline through Week 10
|
|
Incremental Area Under the Curve (iAUC, mmol/L·min)
기간: Baseline through Week 10
|
Incremental area under the glucose curve measured using continuous glucose monitoring.
iAUC represents the area under the glucose curve above the pre-meal baseline during the 2-hour period following a meal.
Higher values indicate greater overall postprandial glucose exposure.
|
Baseline through Week 10
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 7월 1일
기본 완료 (추정된)
2027년 7월 1일
연구 완료 (추정된)
2027년 7월 1일
연구 등록 날짜
최초 제출
2026년 7월 2일
QC 기준을 충족하는 최초 제출
2026년 7월 15일
처음 게시됨 (실제)
2026년 7월 17일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 7월 17일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 7월 15일
마지막으로 확인됨
2026년 7월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NUS-IRB-2026-0409
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
대사 증후군 (METS)에 대한 임상 시험
-
Istanbul Medipol University Hospital완전한
-
Icahn School of Medicine at Mount SinaiNational Institute on Deafness and Other Communication Disorders (NIDCD)완전한
-
Beijing Friendship Hospital모병
-
National University Health System, Singapore모병대사 증후군 | 대사 증후군 (METS)싱가포르
-
Sun Yat-sen University아직 모집하지 않음
-
University of Castilla-La Mancha모병
-
Meihua JiThe Luhe Teaching Hospital of the Capital Medical University모병
-
Meihua JiThe Luhe Teaching Hospital of the Capital Medical University초대로 등록
-
Recep Tayyip Erdogan University Training and Research...아직 모집하지 않음
-
University of Lahore완전한이상지질혈증 | 대사 증후군 (METS)파키스탄
Time-restricted eating에 대한 임상 시험
-
University of ArkansasNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)완전한
-
University of EdinburghNHS Tayside완전한
-
Lawson Health Research Institute완전한
-
Aalborg University HospitalLund University; Catholic University of the Sacred Heart; University of Lausanne Hospitals; Universitat Autonoma de Barcelona 그리고 다른 협력자들알려지지 않은
-
Nicole Matthews, Ph.D.Arizona State University; Southwest Autism Research & Resource Center모병
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...모병
-
Oregon Research Behavioral Intervention Strategies...Oregon Research Institute완전한
-
Weill Medical College of Cornell UniversityMedistim ASA모병CABG | 심장 질환 | 혈류 | CABG 그래프트 무결성 | 이행시간 유량 측정미국
-
Oregon Research Behavioral Intervention Strategies...National Institute on Minority Health and Health Disparities (NIMHD)완전한